Nurix Therapeutics (NRIX) announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology (PFE) and as Chief Medical Officer and interim Chief Executive Officer of Seagen (SGEN).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics announces presentation of new data on NX-1607
- Promising Data from Nurix Therapeutics’ Bexobrutideg Supports Buy Rating
- Nurix Therapeutics’ Bexodeg: Promising Efficacy and Safety Profile Drive Buy Rating
- Nurix Therapeutics price target lowered to $28 from $33 at H.C. Wainwright
- Nurix Therapeutics’ NX-1607 Study: A Potential Game-Changer in Cancer Treatment